Company news

Moleculin Biotech, Inc. news in 2026

Moleculin Biotech, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting

November 4, 2026

Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027

October 30, 2026

Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial

October 20, 2026

Moleculin Announces Reverse Stock Split

October 16, 2026

Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit

October 7, 2026

Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

September 29, 2026

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

September 28, 2026

Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR

September 25, 2026

Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

September 23, 2026

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

September 11, 2026

Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

August 27, 2026

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

August 14, 2026

Moleculin Announces Pricing of $9.3 Million Public Offering

July 31, 2026

Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

July 31, 2026

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment

July 6, 2026

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

June 30, 2026

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment

June 3, 2026

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

May 29, 2026

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

May 21, 2026

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

May 15, 2026

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

May 13, 2026

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

May 12, 2026

Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin

May 8, 2026

Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026

April 23, 2026

Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting

April 21, 2026

Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile

April 6, 2026

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

March 22, 2026

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

March 18, 2026

Moleculin to Present at 38th Annual ROTH Conference

March 17, 2026

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study

March 10, 2026

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

February 19, 2026

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

February 18, 2026

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

February 17, 2026

Moleculin Launches CEO Corner Platform to Share Strategic Insights

February 13, 2026

Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

February 5, 2026

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

January 13, 2026

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

January 12, 2026

Decks in 2026